Alivexis is at the forefront of drug discovery, focusing on small-molecule targeted therapeutics that leverage advanced biological insights and cutting-edge technologies. The company employs sophisticated structural analysis and supercomputing capabilities to address challenging biological targets, which enhances the development of therapeutic candidates. Their pipeline includes innovative projects targeting cancer, immune-inflammatory diseases, and rare diseases, with a strong emphasis on developing modulators of innate immunity and selective inhibitors for oncogenic driver kinases. Notable projects include the development of non-covalent inhibitors and highly specific compounds that demonstrate efficacy in various disease models, showcasing Alivexis's commitment to addressing unmet medical needs.

The company’s research and development operations are supported by a globally networked team of experts with extensive experience in pharmaceutical and biotechnology sectors. Alivexis is actively engaged in partnerships to further its drug discovery initiatives, utilizing a robust platform technology that has successfully produced unique clinical candidates. Their focus on collaboration underscores their strategic approach to advancing therapeutic solutions, with ongoing projects that explore novel mechanisms of action and potential applications across a wide range of diseases. This comprehensive strategy positions Alivexis as a key player in the biopharmaceutical landscape, dedicated to delivering innovative treatments to patients in need.

Japan

Alivexis, Inc. (formerly Modulus Discovery, Inc) is a technology-driven drug discovery enterprise with operational foundations in both Japan and the US. By merging state-of-the-art drug discovery platforms with profound knowledge of disease biology and a dynamic global business approach, we are propelling forward our distinct portfolio of small molecule drugs along with a variety of research and development collaborations.

Alivexis

Company Details